Trulicity Guide

How Trulicity Works

Dulaglutide is a long-acting GLP-1 receptor agonist engineered by fusing two modified GLP-1 peptide chains to a human IgG4 Fc fragment, which extends the half-life to about five days and allows once-weekly dosing. By activating GLP-1 receptors, dulaglutide stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and modestly reduces appetite. The blood-sugar-lowering effect is the labeled indication; the weight reduction is a secondary effect that is smaller than what is seen with semaglutide or tirzepatide.^[2]

Dosing Schedule

Trulicity uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label^[1].

Side Effects

Clinical Trial Results

“

The AWARD program comprised the pivotal phase 3 trials supporting Trulicity's approval and label expansions, evaluating dulaglutide as monotherapy and in combination with metformin, sulfonylureas, insulin, and SGLT2 inhibitors across more than 10 studies. AWARD-7 (Tuttle et al. Lancet Diabetes Endocrinol 2018, PMID 29910024) showed dulaglutide was noninferior to insulin glargine for HbA1c reduction in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, with less weight gain and a lower hypoglycemia rate. SUSTAIN-7 (Pratley et al. Lancet Diabetes Endocrinol 2018, PMID 29397376) directly compared once-weekly semaglutide to dulaglutide; semaglutide produced greater reductions in HbA1c and body weight at matched dose levels. The landmark REWIND cardiovascular outcomes trial (Gerstein et al. Lancet 2019, PMID 31189511) randomized 9,901 adults with type 2 diabetes — most without established CVD — and showed a 12% relative reduction in major adverse cardiovascular events with dulaglutide 1.5 mg over a median follow-up of 5.4 years (HR 0.88, 95% CI 0.79–0.99). REWIND remains the largest and longest GLP-1 CVOT and the first to demonstrate CV benefit in a primary-prevention diabetes population, though the effect size was the smallest in the GLP-1 CVOT class.^[2]

Where to Get Trulicity

These telehealth providers offer access to dulaglutide or compounded equivalents with online consultations and home delivery.

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded dulaglutide from licensed 503A and 503B pharmacies is legal under federal compounding law^[3], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List^[4]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502^[5]. Prices may vary based on dose and promo availability.

Trulicity Head-to-Head Comparisons

Short-form verdict pages comparing Trulicity to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

See all drug-vs-drug verdicts.

Pivotal Trulicity Trial Walkthroughs

Endpoint-by-endpoint breakdowns of the trials that shaped the Trulicity label, with primary-source numbers and FAQs.

Ranked PubMed Studies on Trulicity

Curated lists of the highest-impact peer-reviewed studies on Trulicity and related GLP-1 drugs. Every PMID live-verified via PubMed esummary.

Related Research on Trulicity

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Frequently Asked Questions